Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 253 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Foodie Friday: Pumpkin EVERYTHING! October 8, 2021 ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer? February 23, 2023 FDA Approves Pembrolizumab with Chemotherapy for Primary Advanced or Recurrent Endometrial... July 24, 2024 Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative... June 30, 2025 Load more HOT NEWS News digest – larger waistlines and prostate cancer, GP gut instincts... Breast Cancer Centers Rarely Follow National Screening Recommendations, Study Says EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical... ¿Puede el uso de un microondas causar cáncer?
